Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Description

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Conditions

Engraftment Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Condition
Engraftment Syndrome
Intervention / Treatment

-

Contacts and Locations

Detroit

Henry Ford Health System, Detroit, Michigan, United States, 48202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * • Patients 18-80 years of age with a diagnosis of a hematological malignancy
  • * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
  • * • Patients enrolled in investigational clinical trials
  • * Sct for non hematologic malignancies

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Henry Ford Health System,

Study Record Dates

2026-12-30